Former United States Securities and Exchange Commission attorney Willie Briscoe and the securities litigation firm of Powers Taylor LLP are investigating potential claims against the Board of Directors of Chelsea...
Law office of Brodsky & Smith, LLC announces that it is investigating potential claims against the Board of Directors of Chelsea Therapeutics International, Ltd.
Levi & Korsinsky is investigating the Board of Directors of Chelsea Therapeutics International, Ltd.
Newman Ferrara LLP is investigating potential claims against the board of directors of Chelsea Therapeutics International (“Chelsea”) (Nasdaq: CHTP) concerning the proposed sale of Chelsea to Danish corporation H.
The securities litigation law firm of Brower Piven, A Professional Corporation, has commenced an investigation into possible breaches of fiduciary duty to current shareholders of Chelsea Therapeutics International, Ltd.
Kirby McInerney LLP is investigating potential claims against the Board of Directors of Chelsea Therapeutics International, Ltd.
Levi & Korsinsky is investigating the Board of Directors of Chelsea Therapeutics International, Ltd.
Central nervous system disorder specialist Chelsea Therapeutics International on Thursday said it had signed up to a bid from Denmark's H. Lundbeck that values its stock at up to $658 million.
Chelsea Therapeutics (CHTP) soared Thursday amid news that Danish pharmaceutical company H. Lundbeck would takeover the company for up to $658 million.
Chelsea CEO Joe Oliveto and his team deserve a lot of credit for cleaning up some messy Northera clinical trials, scoring at the FDA advisory panel, securing the drug's approval and now delivering on the exit strategy that everyone wanted.
Legendary investor Warren Buffett advises to be fearful when others are greedy, and be greedy when others are fearful. One way we can try to measure the level of fear in a given stock is through a technical analysis indicator called the Relative Strength Index, or RSI, which measures momentum on a scale of zero to 100.
Investors in Chelsea Therapeutics International Ltd saw new options begin trading this week, for the May 17th expiration. At Stock Options Channel, our YieldBoost formula has looked up and down the CHTP options chain for the new May 17th contracts and identified one put and one call contract of particular interest.
Wedbush believed that Chelsea Therapeutics International is an attractive acquisition or partnership target for multiple pharmaceutical companies because of the approval of NortheraThe stock price of ...
Cramer is staying away from Solazyme but thinks Retrophin is too frothy.
Cramer will be watching a number of conferences for a read on the economy.
Biotech columnist Adam Feuerstein answers readers' questions about health care companies.
Northera treats a rare condition which causes low blood pressure upon standing.
Chelsea Therapeutics International, Ltd. (Nasdaq: CHTP) today announced that the U.
Last month's overwhelmingly positive advisory panel should be enough to prod FDA into approving Chelsea's drug.
